Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of Chronic Diseases
4.2.2 Technological Advancements in Development of Anticoagulant Products
4.2.3 Growing Adoption of Novel Oral Anticoagulants (NOACs)
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 Side Effects Associated with Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Class
5.1.1 Novel Oral Anticoagulants (NOACs)
5.1.2 Heparin and Low Molecular Weight Heparin (LMWH)
5.1.3 Vitamin K Antagonist
5.2 By Application
5.2.1 Atrial Fibrillation/Myocardial Infarction (Heart Attack)
5.2.2 Deep Vein Thrombosis (DVT)
5.2.3 Pulmonary Embolism
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.2 Bayer AG
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Bristol-Myers Squibb Company
6.1.5 Daiichi Sankyo Company
6.1.6 Abbott Laboratories
6.1.7 Aspen Holdings
6.1.8 Sanofi
6.1.9 Pfizer, Inc
6.1.10 Alexion Pharmaceuticals Inc.?
6.1.11 Leo Pharma AS?
6.1.12 Dr. Reddy’s Laboratories?


7 MARKET OPPORTUNITIES AND FUTURE TRENDS